

Table S1. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD4+ T cell responses following two and three COVID-19 vaccine doses.

Variable	Outcome measures					
	% Spike-responsive CD4+ T cells after two vaccine doses			% Spike-responsive CD4+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.29	0.17	0.08	-0.06	0.10	0.58
Age (per year)	0.001	0.004	0.83	-0.004	0.002	0.08
Male sex	0.13	0.14	0.38	0.24	0.084	0.0044
White ethnicity	-0.19	0.14	0.16	-0.045	0.076	0.55
Health conditions (per condition) ^a	-0.03	0.08	0.72	0.11	0.047	0.022
ChAdOx1-containing initial vaccine regimen ^b	0.37	0.21	0.09	0.14	0.12	0.27
Days between 1st and 2nd vaccine dose (per day)	0.005	0.003	0.12	0.002	0.002	0.30
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.17	0.077	0.033
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	0.001	0.001	0.47
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.71	0.058	<2x10⁻¹⁶

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart. ^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine). ^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2).

Table S2. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD8+ T cell responses following two and three COVID-19 vaccine doses.

Variable	Outcome measures					
	% Spike-responsive CD8+ T cells after two vaccine doses			% Spike-responsive CD8+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.0002	0.16	0.99	-0.24	0.12	0.045
Age (per year)	-0.001	0.004	0.87	0.001	0.004	0.87
Male sex	0.18	0.14	0.20	0.11	0.10	0.24
White ethnicity	0.14	0.13	0.30	-0.01	0.08	0.90
Health conditions (per condition) ^a	-0.02	0.08	0.75	-0.05	0.06	0.37
ChAdOx1-containing initial vaccine regimen ^b	0.39	0.20	0.049	0.22	0.14	0.12
Days between 1st and 2nd vaccine dose (per day)	0.002	0.003	0.54	0.00	0.00	0.16
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.02	0.11	0.86
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	-0.001	0.002	0.43
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.79	0.07	<2e-16

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart. ^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine). ^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2).

Table S3. Multivariable logistic regression looking at factors associated with risk of first breakthrough infection between 1 and 6 months following receipt of the 3rd COVID-19 vaccine dose.

Variables	Estimate	95% CI	P value
PLWH group	0.93	0.30 to 2.78	0.89
Age (per year)	0.96	0.93 to 0.98	0.002
Male sex	0.68	0.27 to 1.66	0.40
White ethnicity	1.55	0.69 to 3.60	0.29
Health conditions (per condition) ^a	1.22	0.72 to 2.09	0.46
ChAdOx1-containing initial vaccine regimen ^b	2.02	0.52 to 8.27	0.31

Days between 1st and 2nd vaccine dose (per day)	1.00	0.97 to 1.02	0.76
mRNA-1273 as third vaccine dose ^c	1.09	0.49 to 2.47	0.84
Days between 2nd and 3rd vaccine dose (per day)	1.00	0.99 to 1.01	0.96
% Spike specific CD4+ T cells after three doses (per 1% increment)	0.76	0.25 to 2.13	0.61
% Spike specific CD8+ T cells after two doses (per 1% increment)	0.86	0.36 to 2.01	0.73
Virus neutralizing activity (per 1% increment)	1.00	0.99 to 1.00	0.26

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart. ^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine). ^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2).




Figure S1. Gating strategy for quantification of SARS-CoV-2 spike-specific CD4+ and CD8+ T cells using an activation induced marker (AIM) assay.




Figure S2. Correlations between vaccine-induced spike-specific T cell responses and recent or nadir CD4+ T cell count in PLWH.